Condition: Bipolar Depression · Sponsor: Douglas Mental Health University Institute
Bipolar disorder (BD) is a frequent and lifelong recurrent mood disorder with treatment-resistant depressive episodes. Importantly, depressive symptoms and cognitive decline are major determinants of functionality and quality of life in this clinical population. There is robust evidence that individuals with BD have neurocognitive deficits (especially in memory and executive functioning domains) compared to the healthy population. These deficits are present in all mood states and can greatly affect patients' functional capacity, often more so than mood symptoms themselves. Many pharmacological treatments for BD adversely affect cognition, and those that are beneficial can be difficult to use. There is thus a pressing need to identify a safe, easy-to-use medication that can target both cognitive deficits and depressive symptoms in BD. It is expected that Brexpiprazole adjunctive treatment will be efficacious in treating BD type I and type II depression by improving mood symptoms, as well as cognitive capacity and global functioning, and that such changes will be accompanied by concurrent alterations in associated brain structures.
This description comes directly from the study's public registry record.
Nada Khalil, BA · 514 444 5397 · nada.khalil.comtl@ssss.gouv.qc.ca
Paola Lavin Gonzalez, MD, MSc · 438 389 8181 · maria.lavingonzalez@mail.mcgill.ca
Always discuss trial participation with your own doctor first.
| McMaster University | Hamilton, Ontario, Canada | Terminated |
| Jewish General Hospital | Montreal, Quebec, Canada | Withdrawn |
| Douglas Mental Health University Institute | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04569448